Grail Inc (GRAL)
NASDAQ:GRAL
Want to see GRAL full AI Analyst Report?
GRAL Stock Chart & Stats
$51.71
-$1.19(-6.66%)
At close: 4:00 PM EST
$51.71
-$1.19(-6.66%)
Day’s Range― - ―
52-Week Range$29.95 - $118.84
Previous CloseN/A
Volume371.20K
Average Volume (3M)627.54K
Market Cap
$3.08B
Enterprise Value$3.06B
Total Cash (Recent Filing)$823.11M
Total Debt (Recent Filing)$51.03M
Price to Earnings (P/E)―
Beta2.47
Next Earnings
Aug 18, 2026EPS Estimate
-2.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.37
Shares Outstanding42,916,590
10 Day Avg. Volume720,402
30 Day Avg. Volume627,545
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue19.59
Enterprise Value/Gross Profit-132.36
Enterprise Value/Ebitda-8.48
Forecast
1Y Price Target
$66.71Price Target Upside29.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-10.65
Revenue Forecast (FY)$180.11M
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceManagement highlighted a substantial reduction in late-stage cancer detections in the test arm and a marked increase in early-stage findings, supporting the test's potential clinical value and persuasiveness to payers and clinicians.
Commercial MomentumManagement maintained revenue growth guidance for Galleri and plans to expand the U.S. commercial sales force, indicating sustained commercial traction and potential upside to testing volume.
Leadership And Regulatory ExpertiseAnalyst notes that the appointment of Josh Ofman preserves leadership continuity and brings deep experience in regulatory and reimbursement strategy that could accelerate clinical, regulatory, and commercial progress.
Bears Say
Funding UncertaintyA planned external investment from Samsung remains incomplete due to challenges at a government agency, leaving anticipated funding uncertain and pressuring liquidity planning.
Trial Outcome And Reimbursement UncertaintyNHS-Galleri did not meet its primary endpoint, creating uncertainty about how payers will interpret the evidence and complicating the path to broad reimbursement such as Medicare coverage.
Valuation And Cash Flow RiskThe stock has run up to a premium relative to diagnostic peers while cash burn remains a concern despite reductions, limiting near-term upside and increasing execution risk.
GRAIL Inc News
GRAL FAQ
What was Grail Inc’s price range in the past 12 months?
Grail Inc lowest stock price was $29.95 and its highest was $118.84 in the past 12 months.
What is Grail Inc’s market cap?
Grail Inc’s market cap is $3.08B.
When is Grail Inc’s upcoming earnings report date?
Grail Inc’s upcoming earnings report date is Aug 18, 2026 which is in 79 days.
How were Grail Inc’s earnings last quarter?
Grail Inc released its earnings results on May 05, 2026. The company reported -$2.29 earnings per share for the quarter, beating the consensus estimate of -$2.763 by $0.473.
Is Grail Inc overvalued?
According to Wall Street analysts Grail Inc’s price is currently Undervalued.
Does Grail Inc pay dividends?
Grail Inc does not currently pay dividends.
What is Grail Inc’s EPS estimate?
Grail Inc’s EPS estimate is -2.75.
How many shares outstanding does Grail Inc have?
Grail Inc has 42,916,590 shares outstanding.
What happened to Grail Inc’s price movement after its last earnings report?
Grail Inc reported an EPS of -$2.29 in its last earnings report, beating expectations of -$2.763. Following the earnings report the stock price went up 15.349%.
Which hedge fund is a major shareholder of Grail Inc?
Currently, no hedge funds are holding shares in GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$66.71 (29.01% Upside)
$66.71 (29.01% Upside)
Blogger Sentiment
Bullish
GRAL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
74.40%
12-Months-Change
Fundamentals
Return on Equity
-16.42%
Trailing 12-Months
Asset Growth
-1.55%
Trailing 12-Months
Company Description
Grail Inc
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
GRAL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful clinical and regulatory progress: test volumes grew 50% YoY, screening revenue rose 37% YoY, adjusted gross profit improved 38% YoY, PMA was accepted, and large trial datasets and upcoming ASCO readouts support the evidence base. At the same time, the NHS-Galleri primary combined endpoint was not met, ASP pressure and continued operating losses persist, media scrutiny and competitive activity create near-term headwinds, and regulatory/timing uncertainties (including possible FDA AdCom and CMS coverage) remain. Overall, positives around volume growth, margins improvement, cash runway, partnerships and regulatory progress outweigh the challenges, but the company still faces execution and perception risks that will need to be addressed in coming quarters.View all GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$66.71
▲(29.01% Upside)
Technical Analysis
Ownership Overview
18.81% Insiders
12.44% Mutual Funds
40.81% Other Institutional Investors
14.80% Public Companies and Individual Investors